Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.

Yuan LJ, Li JD, Zhang L, Wang JH, Wan T, Zhou Y, Tu H, Yun JP, Luo RZ, Jia WH, Zheng M.

Cell Death Dis. 2014 May 22;5:e1247. doi: 10.1038/cddis.2014.222. Erratum in: Cell Death Dis. 2015;6:e1784.

2.

Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.

Liu H, Yang Y, Xiao J, Yang S, Liu Y, Kang W, Li X, Zhang F.

Microvasc Res. 2014 May;93:1-8. doi: 10.1016/j.mvr.2014.02.007. Epub 2014 Mar 3.

PMID:
24603190
3.

Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer.

Cao S, Liu W, Li F, Zhao W, Qin C.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6776-83. eCollection 2014.

4.

The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer.

Leisching GR, Loos B, Botha MH, Engelbrecht AM.

Toxicology. 2015 Sep 1;335:72-8. doi: 10.1016/j.tox.2015.07.010. Epub 2015 Jul 19.

PMID:
26201060
5.

Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.

Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, Minegishi T.

Eur J Cancer. 2006 May;42(7):934-47. Epub 2006 Mar 15.

PMID:
16540312
6.

Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.

Shen DY, Zhan YH, Wang QM, Rui G, Zhang ZM.

Liver Int. 2013 Jan;33(1):137-48. doi: 10.1111/liv.12014. Epub 2012 Nov 1.

PMID:
23121546
7.

PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.

Shu XR, Wu J, Sun H, Chi LQ, Wang JH.

Diagn Pathol. 2015 Sep 28;10:177. doi: 10.1186/s13000-015-0404-z.

8.

MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A.

Wang N, Zhou Y, Zheng L, Li H.

Gynecol Oncol. 2014 Jul;134(1):129-37. doi: 10.1016/j.ygyno.2014.04.047. Epub 2014 Apr 30.

PMID:
24793973
9.

Clinicopathological and prognostic significance of Bmi-1 expression in human cervical cancer.

Min L, Dong-Xiang S, Xiao-Tong G, Ting G, Xiao-Dong C.

Acta Obstet Gynecol Scand. 2011 Jul;90(7):737-45. doi: 10.1111/j.1600-0412.2011.01102.x. Epub 2011 Mar 29.

PMID:
21309753
10.

Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer.

Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou L, Guo K.

Oncol Rep. 2015 May;33(5):2337-44. doi: 10.3892/or.2015.3867. Epub 2015 Mar 20.

PMID:
25813398
11.

MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1.

Dong J, Sui L, Wang Q, Chen M, Sun H.

Mol Med Rep. 2014 Sep;10(3):1426-32. doi: 10.3892/mmr.2014.2335. Epub 2014 Jun 16.

PMID:
24939702
12.

Eps8 decreases chemosensitivity and affects survival of cervical cancer patients.

Chen YJ, Shen MR, Chen YJ, Maa MC, Leu TH.

Mol Cancer Ther. 2008 Jun;7(6):1376-85. doi: 10.1158/1535-7163.MCT-07-2388.

13.

Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation.

Ye Y, Xu W, Zhong W, Li Y, Wang C.

Mol Cell Biochem. 2012 Apr;363(1-2):191-202. doi: 10.1007/s11010-011-1171-0. Epub 2011 Dec 7.

PMID:
22147199
14.

Fyn-related kinase expression predicts favorable prognosis in patients with cervical cancer and suppresses malignant progression by regulating migration and invasion.

Zhang X, Li F, Zhu PL.

Biomed Pharmacother. 2016 Dec;84:270-276. doi: 10.1016/j.biopha.2016.09.042. Epub 2016 Sep 22.

PMID:
27665472
15.

T0070907, a PPAR γ inhibitor, induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe.

An Z, Muthusami S, Yu JR, Park WY.

Reprod Sci. 2014 Nov;21(11):1352-61. doi: 10.1177/1933719114525265. Epub 2014 Mar 18.

16.

Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.

Ji J, Zheng PS.

Gynecol Oncol. 2010 Apr;117(1):103-8. doi: 10.1016/j.ygyno.2009.12.020. Epub 2010 Jan 27.

PMID:
20102778
17.

Quercetin induces cytochrome-c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2/M, in cervical carcinoma: signal cascade and drug-DNA interaction.

Bishayee K, Ghosh S, Mukherjee A, Sadhukhan R, Mondal J, Khuda-Bukhsh AR.

Cell Prolif. 2013 Apr;46(2):153-63. doi: 10.1111/cpr.12017.

PMID:
23510470
18.

[Study on RNA interference silencing hMSH2 induces the reversal chemo-resistance of ovarian carcinoma cell line OC3/TAX300].

Wang A, Li J, Li H.

Zhonghua Fu Chan Ke Za Zhi. 2014 Mar;49(3):213-7. Chinese.

PMID:
24820308
19.

GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer.

Ouyang F, Liu J, Xia M, Lin C, Wu X, Ye L, Song L, Li J, Wang J, Guo P, He M.

Oncol Rep. 2017 May;37(5):2652-2662. doi: 10.3892/or.2017.5573. Epub 2017 Apr 11.

20.

Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.

Choi YH, Yoo YH.

Oncol Rep. 2012 Dec;28(6):2163-9. doi: 10.3892/or.2012.2060. Epub 2012 Sep 26.

PMID:
23023313

Supplemental Content

Support Center